Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

The combined use of stereotactic ablative radiotherapy (SABR) and immune checkpoint
inhibitors (ICIs) is an emerging treatment paradigm for oligometastatic non-small-cell lung …

In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical
state has been proposed as an intermediary step along the natural history of cancer with few …

Purpose The aim of this study was to evaluate the outcomes of 68 Ga prostate-specific
membrane antigen (68 Ga-PSMA) positron-emission tomography (PET)/CT-based …

Background Radiotherapy is an emerging treatment strategy for nodal oligorecurrent
prostate cancer (PCa) patients. However, large heterogeneities exist in the RT regimens …

Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer
patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) …

Oligometastatic disease has been described as an intermediate clinical state between
localized cancer and systemically metastasized disease. Recent clinical studies have shown …

Background The role of image-derived biomarkers in recurrent oligometastatic Prostate
Cancer (PCa) is unexplored. This paper aimed to evaluate [18 F] FMCH PET/CT radiomic …

The use of local ablative therapy or metastasis-directed therapy is an emerging
management paradigm in oligometastatic and oligoprogressive cancer. Recent randomized …

Background The use of stereotactic body radiotherapy (SBRT) to definitively treat
oligometastases in prostate cancer has drawn large clinical and research interests within …